Loading...
Loading...
CVAC| Name | Value |
|---|---|
| Revenues | 12.4M |
| Cost of Revenue | 41.7M |
| Gross Profit | -29.3M |
| Operating Expense | 44.9M |
| Operating I/L | -73.3M |
| Other Income/Expense | 3.4M |
| Interest Income | 3.8M |
| Pretax | -69.9M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | -70.6M |
CureVac N.V. is a clinical-stage biopharmaceutical company specializing in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company's primary focus is on developing prophylactic vaccines, including mRNA-based vaccine candidates for SARS-CoV-2, rabies virus glycoprotein, influenza, lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Additionally, CureVac N.V. is involved in the development of RNA-based cancer immunotherapies for treating cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancer of the skin, head, and neck.
